Products
Acipimox is commercially available in the form of capsules (Olbetam). It has been approved in many countries since 1986.
Structure and properties
Acipimox (C6H6N2O3, Mr = 154.1 g/mol) is a derivative of nicotinic acid, which is also active as a lipid-lowering agent.
Effects
Acipimox (ATC C10AD06) has lipid-lowering properties. It lowers triglycerides, cholesterol, LDL, and VLDL and increases HDL. The effects are due in part to inhibition of the release of free fatty acids in adipose tissue (lipolysis). Acipimox also improves sensitivity to insulin (insulin sensitivity).
Indications
For the treatment of dyslipidemia such as hypertriglyceridemia and hypercholesterolemia (hyperlipoproteinemias).
Dosage
According to the SmPC. Capsules are taken two to three times daily after meals.
Contraindications
- Hypersensitivity
- Gastrointestinal ulcers
- Severe renal insufficiency
Full precautions can be found in the drug label.
Interactions
Acipimox is excreted mainly unchanged. Combination with statins is not recommended because it may increase the risk of myopathy.
Adverse effects
The most common possible adverse effects include:
